Acetaminophen and Ascorbate in Sepsis: Targeted Therapy to Enhance Recovery (ASTER)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04291508 |
|
Recruitment Status :
Recruiting
First Posted : March 2, 2020
Last Update Posted : September 14, 2022
|
Sponsor:
Massachusetts General Hospital
Information provided by (Responsible Party):
Boyd Taylor Thompson, Massachusetts General Hospital
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
Prospective multi-center phase 2b randomized placebo-controlled double-blinded interventional platform trial of two different pharmacologic therapies (intravenous Vitamin C or intravenous Acetaminophen) for patients with sepsis-induced hypotension or respiratory failure.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Acute Respiratory Distress Syndrome Critical Illness Respiratory Failure Sepsis | Drug: Intravenous Acetaminophen (room temperature) Drug: Intravenous Vitamin C (refrigerated) Drug: 5% Dextrose (room temperature) Drug: 5% Dextrose refrigerated | Phase 2 |
Hypothesis 1A: Acetaminophen (APAP) or Vitamin C infusion will increase the days alive and free of organ support to day 28.
Hypothesis 1B: APAP or Vitamin C will have a favorable effect on other secondary outcomes including pulmonary and non-pulmonary organ dysfunction and biomarkers of inflammation and endothelial injury
The investigators plan to carry out two multi-center phase 2b randomized double-blinded placebo-controlled trials of two different pharmacologic therapies within a single platform trial.
- One trial will assess the efficacy of Acetaminophen (1 gram intravenously every 6 hours) for 120 hours in patients with sepsis who have evidence of either hemodynamic or respiratory organ failure.
- A second trial will assess the efficacy of Vitamin C (50 mg/kg every 6 hours) infused intravenously for 120 hours in patients with sepsis who have evidence of either hemodynamic or respiratory organ failure.
A total of 900 participants who meet all of the inclusion criteria and none of the exclusion criteria will be randomized in a 2:1:2:1 fashion (APAP-Active: APAP-Placebo: Vit C-Active: Vit C-Placebo). With the closure of the Vitamin C arm in June 2022; the study is proceeding with the APAP and Placebo arms with a 1:1 randomization scheme. The total sample size is 450 participants (225 in the active arm and 225 in the placebo arm).
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 900 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Intervention Model Description: | Patients will be randomized to at a ratio of 2:1 active versus placebo. |
| Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
| Masking Description: | Vitamin C or Vitamin C-placebo will be refrigerated. Acetaminophen or acetaminophen-placebo will be stored at room temperature and the volume will be reduced for patients less than 50 kg. Investigators will be informed of which of the two placebo controlled groups the patient was randomized to. |
| Primary Purpose: | Treatment |
| Official Title: | Acetaminophen and Ascorbate in Sepsis: Targeted Therapy to Enhance Recovery |
| Actual Study Start Date : | October 13, 2021 |
| Estimated Primary Completion Date : | May 2023 |
| Estimated Study Completion Date : | July 2023 |
Resource links provided by the National Library of Medicine
MedlinePlus related topics:
Sepsis
Drug Information available for:
Acetaminophen
| Arm | Intervention/treatment |
|---|---|
|
Active Comparator: IV Acetaminophen-Active
Patients randomized to the Acetaminophen arm will receive Acetaminophen at the dose of 1 gram (or 15 mg/kg if actual body weight < 50kg) in 100 ml 5% dextrose in water every 6 hours intravenously for 5 days (20 doses).
|
Drug: Intravenous Acetaminophen (room temperature)
Acetaminophen given intravenously at the dose of 1 gram (or 15 mg/kg if patient weighs < 50 kg) every six hours for 5 days (20 doses) |
|
Active Comparator: IV Vitamin C-Active
Patients randomized to the Vitamin C arm will receive Vitamin C at the dose of 50 mg/kg in 100 ml 5% dextrose in water every 6 hours intravenously for 5 days (20 doses). Note: This arm is now closed.
|
Drug: Intravenous Vitamin C (refrigerated)
Vitamin C given intravenously at the dose of 50 mg/kg every six hours for 5 days (20 doses)
Other Name: Ascor |
|
Placebo Comparator: Acetaminophen-Placebo
Patients randomized to placebo will receive an identical-appearing intravenous infusion of 100 ml of 5% dextrose in water every 6 hours for 5 days (20 doses).
|
Drug: 5% Dextrose (room temperature)
Placebo (identical appearing room temperature 5% dextrose solution) infused every six hours for 5 days (20 doses) |
|
Placebo Comparator: Vitamin C-Placebo
Patients randomized to placebo will receive an identical-appearing intravenous infusion of 100 ml of 5% dextrose in water every 6 hours for 5 days (20 doses). Note: This arm is now closed.
|
Drug: 5% Dextrose refrigerated
Placebo (identical appearing refrigerated 5% dextrose solution) infused every six hours for 5 days (20 doses) |
Primary Outcome Measures :
- Days alive and free of organ support to day 28 [ Time Frame: 28 days after randomization ]Defined as alive and free of organ support (dialysis, assisted ventilation, and vasopressors) to day 28. Participants will need to be free of all three components (assisted ventilation, vasopressors, new renal replacement therapy) to qualify for a day alive and free from organ failures. Patients on chronic dialysis will not be scored for the new renal failure free component of this outcome.
Secondary Outcome Measures :
- Ventilator-free days (VFD) [ Time Frame: 28 days after randomization ]Ventilator-free days is defined to be 28 days minus the duration of mechanical ventilation through day 28. Participants who do not survive to day 28 are assigned zero ventilator-free days.
- Vasopressor-free days [ Time Frame: 28 days after randomization ]The number of calendar days between randomization and 28 days later that the patient is alive and without the use of vasopressor therapy. Patients who die prior to day 28 are assigned zero vasopressor free days.
- Renal replacement-free days [ Time Frame: 28 days after randomization ]The number of calendar days between randomization and 28 days later that the patient is alive and without new renal replacement therapy. Patients who died prior to day 28 are assigned zero renal replacement free days.
- 28-day hospital mortality [ Time Frame: 28 days after randomization ]
Vital status prior to discharge home before day 28.
"Home" is defined as a patient's place of residence prior to enrollment. Thus, if a patient is discharged to a location that is different from the place of residence prior to enrollment (e.g. rehabilitation facility or hospice) then the patient will be followed until they return to their original location, 90 days, or death, whichever comes first.
- ICU free days [ Time Frame: 28 days after randomization ]The number of days spent alive out of the ICU to day 28.
- Hospital free days to discharge home [ Time Frame: Up to day 28 ]Defined as 28 days minus the number of days from randomization to discharge home. If a patient has not been discharged home prior to study day 28 or dies prior to day 28, hospital free days will be zero. Patients transferred to another hospital or other health care facility will be followed to day 28 to assess this endpoint.
- Days in ICU among survivors and non-survivors [ Time Frame: Up to day 28 ]The total number of days spent in the ICU until hospital discharge or death during the first 28 days. If a patient is discharged alive from the study hospital we assume they are no longer in the ICU
- Number of subjects with initiation of assisted ventilation [ Time Frame: Up to day 28 ]Any patient who received assisted ventilation during the study hospitalization in the first 28 days meets this endpoint.
- Number of subjects with initiation of renal replacement therapy [ Time Frame: Up to day 28 ]Patients who receive (new) renal replacement therapy through day 28 will meet this endpoint. Patients with chronic renal replacement therapy initiated prior to the current sepsis illness will not be eligible to meet this endpoint.
- Change in organ-specific Sepsis-related Organ Failure Assessment (SOFA) scores between enrollment and study day 7 [ Time Frame: Day 0-Day 7 ]We will calculate the SOFA score upon enrollment and at day 7 using clinically available data. If a value is not available at baseline, it will be assumed to be normal. At the day 7 assessment, if a value is missing then we will carry forward the closest previously known value. If a patient is intubated or heavily sedated at either 0 or day 7, the GCS will be omitted when calculating the change in score. If a patient was on renal replacement therapy prior to presentation, then the renal dysfunction component to the SOFA score will be omitted as well
- 90-day hospital mortality [ Time Frame: 90 days after randomization ]Vital status prior to discharge home before day 90.
- Number of subjects who developed ARDS [ Time Frame: Up to day 7 ]Presence and severity of ARDS is determined using the PaO2/FiO2 ratio or SpO2/FiO2 ratio and confirmation of ARDS through chest x-ray reviews.
- Change in serum creatinine concentration [ Time Frame: Up to day 28 ]We will measure the change in serum creatinine from enrollment to discharge, death, initiation of dialysis or 28 days, whichever occurs first
- Number of subjects with Major Adverse Kidney Events at 28 days (MAKE28) [ Time Frame: 28 days after randomization ]Defined as persistent increase in serum creatinine by 200% from baseline, need for new renal replacement therapy, or death
- Change in Radiographic Assessment of Lung Edema (RALE) score [ Time Frame: Up to 72 hours after randomization ]We will determine the change in Radiographic Assessment of Lung Edema (RALE) score from enrollment to 72 hours in patients who are receiving assisted ventilation or high flow nasal oxygen at the time of study randomization
- 90-day all-cause mortality [ Time Frame: 90 days after randomization ]Vital status of the patient at day 90 will be determined using any of the following methods: medical record review, phone calls to patient, proxy or healthcare facility, review of obituaries, or information from the Centers for Disease Control and Prevention's National Death Index (NDI).
- Renal calculi to day 90 [ Time Frame: Up to day 90 ]Renal calculi diagnosed between randomization and study day 90 in patients in the Vitamin C-Active/Vitamin C-Placebo group.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Age ≥ 18 years
-
Sepsis defined as:
- Clinical evidence of a known or suspected infection and orders written to administer antibiotics AND
- Hypotension as defined by the need for any vasopressor (and 1 liter of fluid already administered intravenously for resuscitation) OR respiratory failure defined by mechanical ventilation, BIPAP or CPAP at any level, or greater than or equal to 6 liters/minute of supplemental oxygen (criterion b must be met at time of enrollment)
- Admitted to a study site ICU (or intent for the patient to be admitted to a study site ICU) within 36 hours of presentation to the ED or admitted to the study site ICU within 36 hours of presentation to any acute care hospital
Exclusion Criteria:
- No consent/inability to obtain consent from the participant or a legally authorized representative
- Patient unable to be randomized within 36 hours of presentation to the ED or within 36 hours of presentation to any acute care hospital
- Diagnosis of cirrhosis by medical chart review
- Liver transplant recipient
- AST or ALT greater than five times upper limit of normal
- Diagnosis of ongoing chronic alcohol use disorder/abuse by chart review; if medical record unclear, use Appendix F
- Clinical diagnosis of diabetic ketoacidosis or other condition such as profound hypoglycemia that requires hourly blood glucose monitoring (applicable to the 4 arm (Vitamin C/placebo vs. Acetaminophen/placebo) phase of the trial)
- Hypersensitivity to Acetaminophen or Vitamin C
- Patient, surrogate or physician not committed to full support (Exception: a patient will not be excluded if he/she would receive all supportive care except for attempts at resuscitation from cardiac arrest)
- Home assisted ventilation (via tracheotomy or noninvasive) except for CPAP/BIPAP used only for sleep-disordered breathing
- Chronic dialysis
- Current active kidney stone (applicable to the 4 arm (Vitamin C/placebo vs. Acetaminophen/placebo) phase of the trial)
- Multiple (>1) episodes of prior kidney stones, known history of oxalate kidney stones, or history of oxalate nephropathy. (applicable to the 4 arm (Vitamin C/placebo vs. Acetaminophen/placebo) phase of the trial)
- Kidney transplant recipient (applicable to the 4 arm (Vitamin C/placebo vs. Acetaminophen/placebo) phase of the trial)
- Use of home oxygen >3L/minute via nasal cannula for chronic cardiopulmonary disease
- Moribund patient not expected to survive 24 hours
- Underlying malignancy or other condition with estimated life expectancy of less than 1 month
- Pregnant woman, woman of childbearing potential without a documented negative urine or serum pregnancy test during the current hospitalization, or woman who is breast feeding
- Prisoner
- Treating team unwilling to enroll because of intended use of Acetaminophen or Vitamin C
- Treating team unwilling to use plasma (as opposed to point of care testing) for glucose monitoring (applicable to the 4 arm (Vitamin C/placebo vs. Acetaminophen/placebo) phase of the trial).
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04291508
Contacts
| Contact: Katie Oldmixon, RN | 617-726-4777 | coldmixon@mgh.harvard.edu | |
| Contact: Nancy Ringwood, BSN | 617-724-9836 | nringwood@mgh.harvard.edu |
Locations
Show 42 study locations
Sponsors and Collaborators
Massachusetts General Hospital
Investigators
| Principal Investigator: | Boyd Taylor Thompson, MD | Massachusetts General Hospital |
Additional Information:
| Responsible Party: | Boyd Taylor Thompson, PETAL CCC Principal Investigator, Massachusetts General Hospital |
| ClinicalTrials.gov Identifier: | NCT04291508 |
| Other Study ID Numbers: |
PETAL04ASTER |
| First Posted: | March 2, 2020 Key Record Dates |
| Last Update Posted: | September 14, 2022 |
| Last Verified: | September 2022 |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
Keywords provided by Boyd Taylor Thompson, Massachusetts General Hospital:
|
ARDS Acetaminophen Vitamin C Sepsis |
Additional relevant MeSH terms:
|
Sepsis Toxemia Respiratory Distress Syndrome Respiratory Distress Syndrome, Newborn Respiratory Insufficiency Acute Lung Injury Critical Illness Infections Systemic Inflammatory Response Syndrome Inflammation Pathologic Processes Lung Diseases Respiratory Tract Diseases |
Respiration Disorders Infant, Premature, Diseases Infant, Newborn, Diseases Lung Injury Disease Attributes Acetaminophen Physiological Effects of Drugs Analgesics, Non-Narcotic Analgesics Sensory System Agents Peripheral Nervous System Agents Antipyretics |